Bringing the Oncology Community Together
Cabozantinib Prostate Failure Triggers Massive Exelixis Restructuring
Cabozantinib (Cometriq) failed to significantly extend overall survival compared with prednisone as a treatment for men with metastatic castration-resistant prostate cancer.
Read More >>
Enzalutamide + Sipuleucel-T Gives Immune Boost in mCRPC
Advaxis Scientific Officer Illuminates ADXS-PSA/Pembrolizumab Collaborative Study
Sipuleucel-T Helps ADT Boost Prostate Cancer Immunity
Pembrolizumab Combination Study Planned in Prostate Cancer
Urologist Perspectives Affect Treatments for Prostate Cancer
Prostate Cancer in Younger Men a Separate Phenotype
View More >>
- A Network of Your Peers
View more >>
Biomarkers in the Management of Prostate Cancer
Biopsy, Biomarkers, and Imaging in Prostate Cancer
Prognostic Biomarker Tests for Prostate Cancer
Most Popular Right Now
Tweets by @OncLive
Genomic Testing for Newly Diagnosed Low-Risk Prostate Cancer
E. David Crawford, MD, Steven E. Canfield, MD, Marc A. Dall'Era, MD, and Neal Shore, MD, discuss genomic testing for newly diagnosed, low-risk prostate cancer.
Updates in the Management of CRPC
Moderated by Raoul S. Concepcion, MD, this panel discussion includes expert perspectives from Neal D. Shore, MD, Paul R. Sieber, MD, E. David Crawford, MD, and Mark S. Austenfeld, MD.
American Journal of Managed Care
Oncology Nursing News
Physicians' Education Resource
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright OncLive 2006-2014
Intellisphere, LLC. All Rights Reserved.